Overview

In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.

Eligibility

Inclusion Criteria:

Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.

        ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal:
        creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC >4109/L, HGB>90G/L, and
        PLT>100109/L. Written informed consent
        Exclusion Criteria:
        Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma
        in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy
        or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment
        volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring
        unacceptable risk or affect the compliance of the trial, for example, unstable cardiac
        disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control
        (fasting plasma glucose >1.5×ULN), or emotional disturbance.